Evista rights set to boost Takeda's Asian presence
This article was originally published in Scrip
Executive Summary
Lilly is transferring most of the rights to its osteoporosis product Evista (raloxifene) in seven Asian markets to Takeda, in a move that is set to boost the Japanese firm's commercial operations in the region.